

SUMMARY OF ANALYSIS (SAMPLE ID: SA2020-22576)

Testing Location: OKC 3680 E. I-240 Service Rd. Oklahoma City, OK 73135 License: LAAA-4Y4X-Z72Z	Customer ID: 1832 Lanai Hemp 539 W Commerce St #365 Dallas, TX 75208 License: Hemp Client	Order ID: OR2020-7132 Lot Number: Not Entered Batch Number: Not Entered	Sample Type: Primary Matrix: Oil/Tincture Mass: 30g Date Collected: 02/11/2020 Date Received: 02/13/2020
Cultivar (Strain) or Sample Description: 900mg Tincture			Date Completed: 02/20/2020

*This page is simply a summary of the analysis performed. For analytical details, please consult the individual Certificate(s) of Analysis for each of the specific test(s) performed.

*For Oklahoma, with the new OMMA rules to be effective April 1, 2020, limits on moisture are proposed at 15% and water activity at 0.65aw.

Moisture Content (%) Not Tested	PASS/FAIL N/A	Water Activity (aw) Not Tested	PASS/FAIL N/A
---	-------------------------	--	-------------------------

Cannabinoids (Top 3)	(%)	mg/g
CBD	4.03	40
CBDv	0.0122	0.122
CBDa	0.00168	0.0168
TOTAL CBD	4.04	40
TOTAL THC	0.00159	0.0159
TOTAL CANNABINOIDS	4.05	41

Contaminants	PASS/FAIL
Visual Inspection:	PASS



Scan the QR code to verify results.

This information is provided as a service and makes no claims of efficacy and/or safety of this product.
Results are applicable only for the sample(s) analyzed and for the specific analysis conducted.
This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms.
The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology of Oklahoma City, LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director

CERTIFICATE OF ANALYSIS (SAMPLE ID: SA2020-22576)

Testing Location: OKC 3680 E. I-240 Service Rd. Oklahoma City, OK 73135 License: LAAA-4Y4X-Z72Z	Customer ID: 1832 Lanai Hemp 539 W Commerce St #365 Dallas, TX 75208 License: Hemp Client	Order ID: OR2020-7132 Lot Number: Not Entered Batch Number: Not Entered	Sample Type: Primary Matrix: Oil/Tincture Mass: 30g Date Collected: 02/11/2020 Date Received: 02/13/2020
Cultivar (Strain) or Sample Description: 900mg Tincture			Date Completed: 02/20/2020

CANNABINOID (POTENCY) PROFILE

Analysis Date/Time: 02/17/2020 1654
Analyst: JI

Method: HPLC/DAD
Instrument: Agilent 1100

Moisture Content (%): -
Water Activity (aw): -

<u>Cannabinoid</u>	<u>Result (%)</u>	<u>Result (mg/g)</u>	<u>Reporting Limit (mg/g)</u>	<u>Result (mg/mL)</u>	<u>Per Unit (mg)</u>
CBD	4.03	40.3	0.00281	38.7	1210
CBDa	0.00168	0.0168	0.00281	0.0162	0.505
CBDv	0.0122	0.122	0.00281	0.117	4
Δ9-THC	0.00159	0.0159	0.00281	0.0152	0.476
Δ8-THC	-	-	0.00281	-	-
THCa	-	-	0.00281	-	-
THCv	-	-	0.00281	-	-
CBC	0.00122	0.0122	0.00281	0.0117	0.366
CBG	-	-	0.00281	-	-
CBGa	-	-	0.00281	-	-
CBN	-	-	0.00281	-	-
TOTAL	4.05	41		38.9	1215
TOTAL THC	0.00159	0.0159		0.0152	0.476
TOTAL CBD	4.04	40		38.7	1211




UNIT MASS (g): 30

"-" Not detected above RL.

Cannabinoid Distribution

(% of Total Cannabinoids)



Deviations from standard operating procedure: None

Recoveries for all analyte standards: 90-110%
Replicate Uncertainties: <5% RSD, <20% RPD
Sample/Reagent Blanks: <RL for all analytes

Values for plant matter are adjusted for moisture content.

Total THC = (THCa x 0.877) + Δ9-THC
Total CBD = (CBDa x 0.877) + CBD

Percentage results are reported by mass.
mg/g results are reported as mass component per mass material.

Abbreviations: UV - Ultraviolet, HPLC - High Pressure Liquid Chromatography, RL - Reporting Limit, RPD - Relative Percent Difference, RSD - Relative Standard Deviation

This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms. The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of
Felling Analytical Services and Technology of Oklahoma City, LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director